Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia

Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL. To improve the induction remission rate, we modified the dose of idarubicin in the original Children's Cancer Group (CCG)-1884 protocol, and retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jong Hyung, Park, Jeong Ah, Kim, Eun Kyung, Kang, Hyoung Jin, Shin, Hee Young, Ahn, Hyo Seop
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672129/
https://www.ncbi.nlm.nih.gov/pubmed/19399271
http://dx.doi.org/10.3346/jkms.2009.24.2.281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672129/
https://www.ncbi.nlm.nih.gov/pubmed/19399271
http://dx.doi.org/10.3346/jkms.2009.24.2.281

Ejemplares similares